Tandem Diabetes Care (TNDM) Stock
Insulin pump maker for diabetes patients. Here's the price, business snapshot, and what's worth knowing about Tandem Diabetes Care in October 2026.
Tandem Diabetes Care, Inc. (TNDM) designs and manufactures insulin delivery systems for people with type 1 and advanced type 2 diabetes. Its flagship product, the t:slim X2 insulin pump integrates with continuous glucose monitors and software features such as the Control‑IQ automated insulin delivery algorithm and over‑the‑air updates. The company earns revenue from pump sales, consumable supplies and software-related services and competes on ease of use, interoperability and regulatory approvals. At a market capitalisation of about $1.04 billion, Tandem is a small-cap medical devices company exposed to the growing diabetes care market. Investors should watch device adoption, regulatory milestones, reimbursement trends and partnerships. Key risks include competition from larger device makers, reimbursement uncertainty, supply-chain constraints and the potential for rapid technology change. This is general educational information and not personalised investment advice; consider your own circumstances or speak to a qualified adviser about suitability and risk.
Tandem Diabetes Care (TNDM) Stock Forecast
Analyst price target, next 12 months
$39.25
+105.1% vs today's $19.14
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Tandem Diabetes Care have a consensus 12-month target of $39.25, above the current price of $19.14.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Tandem Diabetes Care's stock, expecting it to rise significantly in value.
Financial Health
Tandem Diabetes Care is performing well with strong revenue and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Device Adoption Trends
Investors may watch increasing pump and CGM adoption as a demand driver, though uptake can vary by region and payer policies.
Software Differentiation
Control‑IQ and over‑the‑air updates can extend product value, but software and regulatory issues may affect performance and approvals.
Market & Reimbursement
Rising diabetes prevalence supports long-term demand; however, reimbursement changes and competition can influence revenue and margins.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
